About: Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s. Phase III trials have shown that the addition of rituximab to CHOP chemotherapy leads to significant improvements in response rate, progression-free survival and overall survival. CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s. Phase III trials have shown that the addition of rituximab to CHOP chemotherapy leads to significant improvements in response rate, progression-free survival and overall survival. (en) CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s. Phase III trials have shown that the addition of rituximab to CHOP chemotherapy leads to significant improvements in response rate, progression-free survival and overall survival. (cs)
Title	Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study (en) Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study (cs)
skos:prefLabel	Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study (en) Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study (cs)
skos:notation	RIV/00179906:_____/07:00000221!RIV08-MZ0-00179906
http://linked.open.../vavai/riv/strany	111;118
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NR8231), Z(MZ0FNHK2005)
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2008
http://linked.open...aciTvurceVysledku	Štěpánková, Pavla Sýkorová, Alice Žák, Pavel Malý, Jaroslav Belada, David Smolej, Lukáš Motyčková, Monika
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Hradec Králové
http://linked.open...dnocenehoVysledku	408558
http://linked.open...ai/riv/idVysledku	RIV/00179906:_____/07:00000221
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	diffuse large B-cell lymphoma; rituximab; non-Hodgkin´s lymphoma; immunochemotherapy (en)
http://linked.open.../riv/klicoveSlovo	immunochemotherapy non-Hodgkin´s lymphoma rituximab diffuse large B-cell lymphoma
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[9C03FF6832AA]
http://linked.open...i/riv/nazevZdroje	Acta Medica (Hradec Králové)
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	7 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...vavai/riv/projekt	Prospective phase II study with combined modality rituximab and intensive chemotherapy followed by HDT with ASCT for poor prognostic B-cell aggressive lymphomas. Analysis of incidence, prognosis and therapy for NHL in Czech Republic.
http://linked.open...UplatneniVysledku	2007
http://linked.open...v/svazekPeriodika	50
http://linked.open...iv/tvurceVysledku	Malý, Jaroslav Žák, Pavel Štěpánková, Pavla Belada, David Smolej, Lukáš Hrudková, Monika Sýkorová, Alice
http://linked.open...n/vavai/riv/zamer	Nové diagnostické indikátory a léčebné postupy v závislosti na různých obdobích života s důrazem na stáří
issn	1211-4286
number of pages	8 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma a single-center, retrospective study

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software